Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RENB-HV-21
- Development stage
- Preclinical
- Lead developer
- Renovaro
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
**RENB-HV-21** is a preclinical allogeneic cellular immunotherapy being developed for **HIV infection**. The candidate combines allogeneic natural killer cells and gamma delta T cells, aiming to use their innate and cytotoxic anti-HIV activity to suppress or eliminate HIV-infected cells and support durable viral control. The program was licensed from Seraph Research Institute and developed by Renovaro, now Lunai Bioworks; an investigator-initiated pre-IND interaction was completed in October 2021. Public filings describe the HIV pipeline as deprioritized rather than discontinued, and no human clinical trial or approved product has been confirmed. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1527728/000173112223001770/e5061_10k.htm))
- Other names
- RENB-HV21RENB-HV-21RENB-HV 21
Beyond the preview
Go deeper on RENB-HV-21.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RENB-HV-21.